Neurocrine Biosciences Stock Probability of Future Stock Price Finishing Under 133.05
| NBIX Stock | USD 136.91 0.08 0.06% |
Neurocrine |
Neurocrine Biosciences Target Price Odds to finish below 133.05
The tendency of Neurocrine Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 133.05 or more in 90 days |
| 136.91 | 90 days | 133.05 | under 95 |
Based on a normal probability distribution, the odds of Neurocrine Biosciences to drop to $ 133.05 or more in 90 days from now is under 95 (This Neurocrine Biosciences probability density function shows the probability of Neurocrine Stock to fall within a particular range of prices over 90 days) . Probability of Neurocrine Biosciences price to stay between $ 133.05 and its current price of $136.91 at the end of the 90-day period is under 4.
Given the investment horizon of 90 days Neurocrine Biosciences has a beta of 0.92. This indicates Neurocrine Biosciences market returns are sensitive to returns on the market. As the market goes up or down, Neurocrine Biosciences is expected to follow. Additionally Neurocrine Biosciences has an alpha of 0.2052, implying that it can generate a 0.21 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Neurocrine Biosciences Price Density |
| Price |
Predictive Modules for Neurocrine Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Neurocrine Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Neurocrine Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Neurocrine Biosciences is not an exception. The market had few large corrections towards the Neurocrine Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Neurocrine Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Neurocrine Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.21 | |
β | Beta against Dow Jones | 0.92 | |
σ | Overall volatility | 6.80 | |
Ir | Information ratio | 0.12 |
Neurocrine Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Neurocrine Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Neurocrine Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Neurocrine Biosciences is unlikely to experience financial distress in the next 2 years | |
| Neurocrine Biosciences has a strong financial position based on the latest SEC filings | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Neurocrine Biosciences Announces U.S. Launch of CRENESSITY for Classic Congenital Adrenal ... |
Neurocrine Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Neurocrine Stock often depends not only on the future outlook of the current and potential Neurocrine Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neurocrine Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 101 M | |
| Cash And Short Term Investments | 1 B |
Neurocrine Biosciences Technical Analysis
Neurocrine Biosciences' future price can be derived by breaking down and analyzing its technical indicators over time. Neurocrine Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Neurocrine Biosciences. In general, you should focus on analyzing Neurocrine Stock price patterns and their correlations with different microeconomic environments and drivers.
Neurocrine Biosciences Predictive Forecast Models
Neurocrine Biosciences' time-series forecasting models is one of many Neurocrine Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Neurocrine Biosciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Neurocrine Biosciences
Checking the ongoing alerts about Neurocrine Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Neurocrine Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Neurocrine Biosciences is unlikely to experience financial distress in the next 2 years | |
| Neurocrine Biosciences has a strong financial position based on the latest SEC filings | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Neurocrine Biosciences Announces U.S. Launch of CRENESSITY for Classic Congenital Adrenal ... |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.